{"id":"W3203496479","doi":"10.1016/j.annonc.2021.08.1348","title":"963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"Stand Up To Cancer; Kom op tegen Kanker; Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Internal medicine; Population; Multicenter trial; Progressive disease; Phases of clinical research; Interim analysis; Salvage therapy; Clinical trial; Minimal residual disease; Surgery; Bone marrow; Chemotherapy; Randomized controlled trial; Multicenter study","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001457256,0.0007154843,0.001270001,0.0002993029,0.0002292856,0.0009116942,0.0004934133,0.0005097361,0.003017079],"category_scores_gemma":[0.001009714,0.0002036775,0.001126737,0.0005376145,0.0003556142,0.0006567702,0.000287283,0.001936377,0.0006851704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006914621,"about_ca_system_score_gemma":0.0009633276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00122498,"about_ca_topic_score_gemma":0.006343395,"domain_scores_codex":[0.9996371,0.0001658047,0.00002767164,0.00004641195,0.00006252586,0.00006040267],"domain_scores_gemma":[0.9995326,0.000122779,0.0001408723,0.00004046395,0.00004711939,0.0001162567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4008647,0.005849605,0.02013202,0.003902572,0.007284299,0.000350022,0.0002825281,0.004453782,0.02742803,0.0009846285,0.02514527,0.5033225],"study_design_scores_gemma":[0.5888517,0.1873328,0.1128294,0.001130175,0.008818223,0.002269528,0.0003815611,0.004575789,0.01114226,0.002425284,0.08005902,0.0001840592],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9466165,0.03226713,0.0008821542,0.002066182,0.0005783805,0.0009814472,0.006402067,0.0001963694,0.01000981],"genre_scores_gemma":[0.9519825,0.02301901,0.002187635,0.002391217,0.0003048613,0.0008641094,0.01353393,0.0000856957,0.005631156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003017079,"threshold_uncertainty_score":0.01009309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1351606975645585,"score_gpt":0.4364078917801264,"score_spread":0.3012471942155679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}